Publications While At Healthpartners
Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1)
Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
Diabetes, Obesity & Metabolism.
Double-blind mealtime faster-acting insulin aspart vs. insulin aspart in basal-bolus improves glycemic control in T1D: the Onset 1 Trial [abstract #293-OR]
Superior reduction of HbA1c in a double-blind, randomized study of basal insulin peglispro (BIL) vs. insulin glargine (GL) in patients (pts) with T1D: IMAGINE 3 [abstract]
Map of science